Special Issue "Latest Development in Multiple Myeloma"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 15 October 2019

Special Issue Editor

Guest Editor
Assoc. Prof. Dr. Yoichi Imai

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Website | E-Mail
Interests: multiple myeloma; HDAC inhibitor; IMiDS; MRD; biomarker

Special Issue Information

Dear Colleagues,

Multiple myeloma is an incurable B-cell malignancy frequently accompanied by many complications, like osteolytic lesions and renal failures. In the age of novel anti-myeloma drugs, including proteasome inhibitors and immunomodulatory drugs, the response rate and survival duration have been improved. In addition, immunotherapy using therapeutic antibodies and CAR-T cells has led to a great advance in the treatment of release/refractory patients. This Special Issue will discuss recent developments in our understanding of the biology and genomic characteristics, detection of minimal residual disease, innovations in the field of multiple myeloma.

Assoc. Prof. Dr. Yoichi Imai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top